


1. -22. (Canceled)

23. (Currently Amended) A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has the following structure:



wherein:

X=a bond,  $(CH_2)_n$ , O, S, or  $O(CH_2)_n$ ; O, or  $O(CH_2)_n$ ,

wherein n=1-6;

R<sub>1</sub>=C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>;


R<sub>2</sub>=F or COOR<sub>5</sub>,

wherein R<sub>5</sub> is C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>;

R<sub>3</sub>=CH<sub>3</sub> or  $(CH_2)_n-COOR_6$ ,

wherein n=1-6 and R<sub>6</sub> is C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>;

R<sub>4</sub>= $(CH_2)_n-COR_7R_8$ ,  $(CH_2)_n-R_{10}R_{11}$  or



R<sub>7</sub>=O, NH, or NR<sub>9</sub>,

R<sub>8</sub>=optionally substituted aryl or heterocycle,

R<sub>9</sub>=C<sub>1-6</sub>-alkyl,

R<sub>10</sub>=O, S, SO, SO<sub>2</sub>, NH, or NR<sub>12</sub>,

R<sub>11</sub>=aryl or heterocyclyl optionally substituted with  $(CH_2)_nCOOR_{14}$ ,

R<sub>12</sub>=C<sub>1-6</sub>-alkyl, optionally substituted with OH or NH<sub>2</sub>,

R<sub>13</sub>=C<sub>1-6</sub>-alkyl, optionally substituted with OH or NH<sub>2</sub>,


R<sub>14</sub>=C<sub>1-6</sub>-alkyl, optionally substituted with OH or NH<sub>2</sub>,

R<sub>15</sub>= $(CH_2)_nCOOR_{16}$ ,

R<sub>16</sub>=C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>, and


$R_{17}$ =not present or  $COOR_{18}$  wherein  $R_{18}$  is C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>, and wherein n=1-6.

24. (Currently Amended) A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has a formula selected from the group consisting of:




X=bond, CH<sub>2</sub>, or OCH<sub>2</sub>

R=lower alkyl optionally substituted OH or NH<sub>2</sub>;




R=lower alkyl optionally substituted by OH or NH<sub>2</sub>;




n=1 to 3

R=lower alkyl optionally substituted by OH or NH<sub>2</sub>;




n=1 to 3

R=lower alkyl optionally substituted by OH or NH<sub>2</sub>; and




R=lower alkyl optionally substituted by OH or NH<sub>2</sub>, NH<sub>2</sub>;



n=1 to 3 X=O, NH, NR where R is lower alkyl

Y=optionally substituted aryl or heterocyclyl; and




n=0 to 2

X=O, S, SO, SO<sub>2</sub>, NH NR or N(CH<sub>2</sub>)<sub>m</sub>COOH where m is 0 or 2

Y=aryl or heterocyclyl substituted with (CH<sub>2</sub>)<sub>m</sub>COOH where m is 0 to 2.


25. (Original) The compound, according to claim 24, wherein said compound has the following structure:



X=bond, CH<sub>2</sub>, or OCH<sub>2</sub>


R=lower alkyl optionally substituted OH or NH<sub>2</sub>.

26. (Original) The compound, according to claim 24, wherein said compound has the following structure:



R=lower alkyl optionally substituted by OH or NH<sub>2</sub>.


27. (Original) The compound, according to claim 24, wherein said compound has the following structure:



n=1 to 3

R=lower alkyl optionally substituted by OH or NH<sub>2</sub>.


28. (Original) The compound, according to claim 24, wherein said compound has the following structure:



n=1 to 3

R=lower alkyl optionally substituted by OH or NH<sub>2</sub>.

29. (Original) The compound, according to claim 24, wherein said compound has the following structure:




R=lower alkyl optionally substituted by OH or NH<sub>2</sub>.

30. – 31. (Canceled)

32. (Previously Presented) The method, according to claim 23, wherein the patient is a human.

33. (Previously Presented) The method, according to claim 23, wherein said method is used to treat a condition selected from the group consisting of hypertension, angina, ischemia, arrhythmia, congestive heart failure, and cardiac insufficiency.

34. (Currently Amended) A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has the following structure:



wherein:

X=a bond, (CH<sub>2</sub>)<sub>n</sub>, O, S, or O(CH<sub>2</sub>)<sub>n</sub>, O, or O(CH<sub>2</sub>)<sub>n</sub>,

wherein n=1-6;

R<sub>1</sub>=C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>;


R<sub>2</sub>=F or COOR<sub>5</sub>,

wherein R<sub>5</sub> is C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>;

R<sub>3</sub>=CH<sub>3</sub> or (CH<sub>2</sub>)<sub>n</sub>-COOR<sub>6</sub>,

wherein n=1-6 and R<sub>6</sub> is C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>;

R<sub>4</sub>=(CH<sub>2</sub>)<sub>n</sub>-COR<sub>7</sub>R<sub>8</sub>, -(CH<sub>2</sub>)<sub>n</sub>-R<sub>10</sub>R<sub>11</sub>-or



$R_7=O, NH,$  or  $NR_8;$

$R_8=$ optionally substituted aryl or heterocycle;

$R_9=C_{1-6}$  alkyl;

$R_{10}=O, S, SO, SO_2, NH,$  or  $NR_{12};$

$R_{11}=$ aryl or heterocycl~~y~~l optionally substituted with  $(CH_2)_nCOOR_{14};$

$R_{12}=C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2;$

$R_{13}=C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2;$

$R_{14}=C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2;$

$R_{15}=$  is H,

$R_{17}=$ not present or  $COOR_{18}$  wherein  $R_{18}$  is  $C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2,$  and  
wherein n=1-6. n=1-6;

provided that when  $R_2$  is fluoro; X is O;  $R_3$  is methyl,  $(CH_2)_{0-4}OR_4$  is  $(CH_2)_3O-C_{1-6}$  alkyl;

